JP2015511963A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511963A5 JP2015511963A5 JP2015500593A JP2015500593A JP2015511963A5 JP 2015511963 A5 JP2015511963 A5 JP 2015511963A5 JP 2015500593 A JP2015500593 A JP 2015500593A JP 2015500593 A JP2015500593 A JP 2015500593A JP 2015511963 A5 JP2015511963 A5 JP 2015511963A5
- Authority
- JP
- Japan
- Prior art keywords
- breast cancer
- hormone receptor
- receptor positive
- triple negative
- dihydropyrazino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611374P | 2012-03-15 | 2012-03-15 | |
| US61/611,374 | 2012-03-15 | ||
| US201261715331P | 2012-10-18 | 2012-10-18 | |
| US61/715,331 | 2012-10-18 | ||
| PCT/US2013/031185 WO2013138553A1 (en) | 2012-03-15 | 2013-03-14 | Treatment of cancer with tor kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017218014A Division JP6470820B2 (ja) | 2012-03-15 | 2017-11-13 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015511963A JP2015511963A (ja) | 2015-04-23 |
| JP2015511963A5 true JP2015511963A5 (cg-RX-API-DMAC7.html) | 2016-04-21 |
Family
ID=48014333
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500593A Pending JP2015511963A (ja) | 2012-03-15 | 2013-03-14 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
| JP2017218014A Active JP6470820B2 (ja) | 2012-03-15 | 2017-11-13 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017218014A Active JP6470820B2 (ja) | 2012-03-15 | 2017-11-13 | Ｔｏｒキナーゼ阻害剤を用いた癌の治療 |
Country Status (19)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| EP3549940A1 (en) | 2013-04-17 | 2019-10-09 | Signal Pharmaceuticals, LLC | Pharmaceutical formulations, of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| MY189663A (en) | 2013-04-17 | 2022-02-23 | Signal Pharm Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
| HK1221168A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用於治疗癌症的包括tor激酶抑制剂和n-(3-(5-氟-2-(4-(2-甲氧基乙氧基)苯基氨基)嘧啶-4-基氨基)苯基)丙烯醯胺的组合疗法 |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| JP6382946B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ，エルエルシー | ジヒドロピラジノ−ピラジンによる癌治療 |
| CA2908742C (en) * | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
| WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| CN107474051B (zh) | 2013-05-29 | 2020-10-30 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| IL271491B2 (en) | 2017-06-22 | 2023-09-01 | Celgene Corp | Treatment of carcinoma of the liver characterized by hepatitis b virus infection |
| CN112933088B (zh) * | 2021-02-03 | 2022-02-22 | 南华大学附属第一医院 | Y041-5921在制备抗肿瘤药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2627352T3 (es) | 2006-10-19 | 2017-07-27 | Signal Pharmaceuticals, Llc | Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas |
| RU2474582C2 (ru) | 2006-10-19 | 2013-02-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы |
| CA2721072A1 (en) * | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer methods employing extracts of gleditsia sinensis lam |
| WO2010022243A1 (en) * | 2008-08-20 | 2010-02-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chemoprevention of head and neck squamous cell carcinomas |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| NZ599549A (en) | 2009-10-26 | 2013-11-29 | Signal Pharm Llc | Methods of synthesis and purification of heteroaryl compounds |
-
2013
- 2013-03-14 EP EP13713003.5A patent/EP2825169B1/en active Active
- 2013-03-14 MY MYPI2014702602A patent/MY178012A/en unknown
- 2013-03-14 WO PCT/US2013/031185 patent/WO2013138553A1/en not_active Ceased
- 2013-03-14 MX MX2014011118A patent/MX360880B/es active IP Right Grant
- 2013-03-14 KR KR1020147028898A patent/KR102057359B1/ko active Active
- 2013-03-14 BR BR112014022707-1A patent/BR112014022707A2/pt not_active IP Right Cessation
- 2013-03-14 TW TW102109151A patent/TWI635862B/zh active
- 2013-03-14 JP JP2015500593A patent/JP2015511963A/ja active Pending
- 2013-03-14 AU AU2013202993A patent/AU2013202993B2/en not_active Ceased
- 2013-03-14 SG SG11201405724RA patent/SG11201405724RA/en unknown
- 2013-03-14 CN CN201380024241.3A patent/CN104271139A/zh active Pending
- 2013-03-14 CA CA2867348A patent/CA2867348A1/en not_active Abandoned
- 2013-03-14 ES ES13713003.5T patent/ES2678250T3/es active Active
- 2013-03-14 US US13/803,305 patent/US20130245027A1/en not_active Abandoned
- 2013-03-14 NZ NZ628407A patent/NZ628407A/en not_active IP Right Cessation
-
2014
- 2014-09-12 NI NI201400112A patent/NI201400112A/es unknown
- 2014-09-12 ZA ZA2014/06701A patent/ZA201406701B/en unknown
- 2014-09-14 IL IL234641A patent/IL234641B/en active IP Right Grant
- 2014-09-15 PH PH12014502046A patent/PH12014502046B1/en unknown
-
2017
- 2017-11-13 JP JP2017218014A patent/JP6470820B2/ja active Active
-
2022
- 2022-10-28 US US17/976,471 patent/US20230338370A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015511964A5 (cg-RX-API-DMAC7.html) | ||
| JP2015516375A5 (cg-RX-API-DMAC7.html) | ||
| JP2015510891A5 (cg-RX-API-DMAC7.html) | ||
| Costa et al. | Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review | |
| JP2021102637A5 (cg-RX-API-DMAC7.html) | ||
| Wicki et al. | First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13) | |
| CN106659765B (zh) | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 | |
| EP2825170B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| TWI708605B (zh) | 以ｔｏｒ激酶抑制劑治療癌症 | |
| AU2013203156B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
| AU2013202992B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
| KR20230049620A (ko) | 교류 전기장에 대한 암세포 민감도를 증가시키기 위한 방법 및 조성물 | |
| EP2825169B1 (en) | Treatment of cancer with tor kinase inhibitors | |
| JP2016516816A5 (cg-RX-API-DMAC7.html) | ||
| Guidetti et al. | Phase II study of sorafenib in patients with relapsed or refractory lymphoma | |
| JP2015534981A5 (cg-RX-API-DMAC7.html) | ||
| EP2961408A1 (en) | Treatment of cancer with tor kinase inhibitors | |
| JP2023522741A (ja) | 併用療法による治療のための患者の選択方法 | |
| Konar et al. | Synthesis and clinical development of palbociclib: An overview | |
| Oberthür et al. | Simultaneous inhibition of IGF1R and EGFR enhances the efficacy of standard treatment for colorectal cancer by the impairment of DNA repair and the induction of cell death | |
| BR112015013196A2 (en) | combinations of a pi3k / akt inhibitor compound with a her3 / egfr inhibitor compound and methods of use | |
| Mortensen et al. | 337 The discovery and preclinical characterization of CC-223, a novel mTOR kinase inhibitor under clinical investigation | |
| Xu et al. | 338 CC-223, a Selective mTOR Kinase Inhibitor, Potently Inhibits Proliferation of a Large Panel of Cancer Cell Lines in Vitro | |
| AU2015213400B2 (en) | Treatment of cancer with TOR kinase inhibitors | |
| Narla et al. | 336 Antitumor Activity of mTOR Kinase Inhibitor CC-223 in a Mouse Model of Glioblastoma |